ClinicalTrials.gg

TargetBeta

HTR2C

5-hydroxytryptamine receptor 2C · also 5-HT2C, 5HTR2C, HTR1C · 5-hydroxytryptamine receptors, G protein-coupled

5 programs in company-led studies act on HTR2C, from 5 companies: 2 in phase 3, 3 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (5 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
cyclobenzaprineruleTonix Pharmaceuticalsphase 4322 runningHTR2AChEMBL
RisperidoneruleJohnson & Johnsonphase 41111 runningDRD2, HTR2AChEMBL
OlanzapineruleEli Lillyphase 4761 runningDRD2, DRD3, DRD4, HTR2AChEMBL
FenfluramineruleUCBphase 3112 runningHTR1D, SIGMAR1ChEMBL
TrazodoneruleAngelini Pharmaphase 3140 runningHTR2A, SLC6A4ChEMBL

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.